Skip to main content
Medical information Clinical review pending

Genetic Testing

PMS1 Gene Nonpolyposis Hereditary Colon Cancer PMS1 Related Genetic Test

Genetic test to identify mutations in the PMS1 gene, associated with an increased risk of hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome. Helps in early detection and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample, Extracted DNA, or One drop of blood on FTA card.
Results
Confirm with the laboratory before booking.
Preparation
A clinical history evaluation and genetic counseling session are recommended before the test. This helps in understanding the family history and the relevance of the test.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the PMS1 Gene Nonpolyposis Hereditary Colon Cancer PMS1 Related Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal or family history of colorectal cancer
  • ✓Diagnosis of colorectal cancer at a young age (e.g., under 50)
  • ✓Multiple family members with Lynch syndrome-associated cancers
  • ✓Family history of other Lynch syndrome-associated cancers (e.g., endometrial, ovarian, stomach)
  • ✓To assess risk for individuals with suspected hereditary cancer syndromes
02

In plain language

What this test helps you understand

Identifies mutations in the PMS1 gene, which are associated with an increased risk of hereditary nonpolyposis colorectal cancer (HNPCC) / Lynch syndrome. This information can guide personalized cancer screening and prevention strategies.
The PMS1 Gene Nonpolyposis Hereditary Colon Cancer PMS1 Related NGS Genetic DNA Test is a genetic analysis designed to detect mutations in the PMS1 gene. Mutations in this gene are linked to an increased risk of developing hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome. Understanding your genetic predisposition is important for proactive health management.

This test utilizes Next-Generation Sequencing (NGS) technology to examine your DNA for specific changes in the PMS1 gene. This comprehensive approach helps identify genetic markers that may indicate a higher likelihood of developing certain cancers, particularly colon cancer.

Discussing your results with a healthcare professional is essential to understand their implications and determine appropriate next steps, which may include increased surveillance or preventive measures.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history evaluation and genetic counseling session are recommended before the test. This helps in understanding the family history and the relevance of the test.
SampleBlood sample, Extracted DNA, or One drop of blood on FTA card.
MethodologyNext-Generation Sequencing (NGS) analysis of the PMS1 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically analyzes the PMS1 gene. It does not detect mutations in other genes associated with hereditary cancer syndromes. A negative result does not completely rule out a genetic predisposition to cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The PMS1 gene is one of several genes involved in DNA repair. Mutations in this gene can increase the risk of developing certain types of cancer, particularly colorectal cancer.
Individuals with a personal or family history of colorectal cancer, especially if diagnosed at a young age, or a family history of other Lynch syndrome-associated cancers, may benefit from this test.
A positive result indicates the presence of a mutation in the PMS1 gene, suggesting an increased risk for certain cancers. It is important to discuss this result with a healthcare provider to understand the implications and recommended next steps.
A negative result means no mutations were detected in the PMS1 gene within the scope of the test. However, it does not completely rule out a genetic predisposition to cancer.
Yes, genetic counseling before and after testing is highly recommended to help understand the test, interpret the results, and discuss implications for personal health and family members.
The sample can be collected as a blood draw, using extracted DNA, or via a single drop of blood on an FTA card.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp